healty adult Parkinson'
Conditions
Interventions
MENESIT100 1tablet once a day (p.o.) famotidine 40mg/day for previous 1day (p.o.) MENESIT100 1tablet once a day (p.o.) esomeprazole 20mg for previous three days or more (p.o.) MENESIT100 1tabl
Sponsors
Utano National Hospital, National Hospital Organaization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects gave consent in writing 2.Subjects between 20 and 75 year of age at the time of obtaining informed consent
Exclusion criteria
Exclusion criteria: 1.Subjects taking H2-receptor antagonists and Proton pump inhibitors 2.Subjects with allergy for L-dopa formulation,H2-receptor antagonists and Proton pump inhibitors 3.Subjects taking drugs that have interaction with L-dopa formulation,H2-receptor antagonists and Proton pump inhibitors 4.Subjects with glaucoma 5.Subjects with liver failure or renal dysfunction 6.Subjects with gastric ulcer,duodenal ulcer or with that history 7.Diabetic 8.Subjects with serious lung disease, serious cardiovascular disease,bronchial asthma or endocrine disorder 9.Subjects with psychiatric symptoms such as suicidal tendencies 10.Dialysis patient 11.Pregnant women or women who may possibly be pregnant 12.Subjects who are judged to be inadequate to participate in this trial at the blood sampling of provisional registration 13.Others, subjects who are judged to be inadequate to participate in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| L-dopa blood concentration in blood collection point of taking L-dopa formulation before, after taking 10,20,30,60,120,240 minutes when taking L-dopa formulation alone, combination with H2-receptor antagonists, combination with Proton pump inhibitors | — |
Countries
Japan
Contacts
Public ContactKaho Yokoyama
Utano National Hospital, National Hospital Organaization Department of Hospital Pharmacy
Outcome results
None listed